Get the Stockscreener App
4.50
7.02%
-0.34
After Hours:
4.72
0.22
+4.89%
Adverum Biotechnologies Inc stock is traded at $4.50, with a volume of 103.64K.
It is down -7.02% in the last 24 hours and up +4.90% over the past month.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
See More
Previous Close:
$4.84
Open:
$4.83
24h Volume:
103.64K
Relative Volume:
0.57
Market Cap:
$93.61M
Revenue:
-
Net Income/Loss:
$-117.17M
P/E Ratio:
-0.3879
EPS:
-11.6
Net Cash Flow:
$-91.71M
1W Performance:
-2.60%
1M Performance:
+4.90%
6M Performance:
-37.76%
1Y Performance:
-75.00%
1-Day Range:
$4.46
$4.85
1-Week Range:
$4.20
$4.905
52-Week Range:
$3.52
$18.50
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Name
Adverum Biotechnologies Inc
Sector
Industry
Phone
(650) 649-1004
Address
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.50 | 93.61M | 0 | -117.17M | -91.71M | -11.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Upgrade | Truist | Hold → Buy |
| Jul-23-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-03-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-29-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Apr-29-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-29-21 | Downgrade | Truist | Buy → Hold |
| Dec-16-20 | Initiated | UBS | Neutral |
| Nov-12-20 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jun-26-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-05-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-16-20 | Initiated | SVB Leerink | Outperform |
| Feb-10-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-10-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Neutral |
| Sep-13-19 | Reiterated | Chardan Capital Markets | Neutral |
| Jun-14-19 | Resumed | Raymond James | Mkt Perform |
| Nov-02-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-02-18 | Downgrade | SunTrust | Buy → Hold |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-30-18 | Initiated | SunTrust | Buy |
| Feb-15-18 | Resumed | Piper Jaffray | Overweight |
| Oct-12-17 | Initiated | Raymond James | Outperform |
View All
Adverum Biotechnologies Inc Stock (ADVM) Latest News
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - Marketscreener.com
Adverum launches phase 3 trial for wet AMD gene therapy By Investing.com - Investing.com UK
Can This One-Time Gene Therapy Revolutionize Wet AMD Treatment? Adverum's Phase 3 Trial Begins - StockTitan
Adverum Biotechnologies initiates ARTEMIS study - TipRanks
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Adverum biotechnologies sees $1.44 million stock purchase by major shareholder - Investing.com
How Adverum is Attracting Talent: New Employees Receive $186,000 in Equity Grants - StockTitan
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Target Price at $27.83 - MarketBeat
Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference - The Manila Times
Gene Therapy Developer Adverum to Showcase Ocular Disease Pipeline at Major Healthcare Conference - StockTitan
Adverum Biotechnologies (NASDAQ:ADVM) Stock Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
3 US Penny Stocks With Market Caps Below $400M - Yahoo Finance
The Sonic Fund Solicits Proxies from Shareholders of Adverum Biotechnologies -April 13, 2021 at 04:16 pm EDT - Marketscreener.com
Adverum Biotechnologies (NASDAQ:ADVM) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
4D’s new data in wet AMD bolster its phase III study vision - BioWorld Online
Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Gene Therapy Pioneer Adverum Takes Center Stage at Major Healthcare Conference - StockTitan
ADVM stock touches 52-week low at $4.01 amid market challenges - MSN
Brokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) PT at $27.83 - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $27.83 Average PT from Analysts - Defense World
Barclays PLC Buys 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Comparing Adverum Biotechnologies (NASDAQ:ADVM) & Pluri (NASDAQ:PLUR) - Defense World
Adverum Biotechnologies stock hits 52-week low at $4.4 - Investing.com
Adverum Biotechnologies stock hits 52-week low at $4.4 By Investing.com - Investing.com South Africa
Geode Capital Management LLC Sells 16,731 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Barclays PLC Purchases 19,965 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
State Street Corp Boosts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Increase in Short Interest - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Large Increase in Short Interest - MarketBeat
Adverum Biotechnologies stock hits 52-week low at $4.61 - Investing.com
Adverum Biotechnologies (NASDAQ:ADVM) Cut to Sell at StockNews.com - Defense World
StockNews.com Downgrades Adverum Biotechnologies (NASDAQ:ADVM) to Sell - MarketBeat
Where are the Opportunities in (ADVM) - Stock Traders Daily
Fmr LLC Lowers Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Sold by Fmr LLC - MarketBeat
Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 - Marketscreener.com
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Down 11.1% in November - MarketBeat
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Drops By 11.1% - Defense World
ADVM stock touches 52-week low at $5.61 amid market challenges - Investing.com
StockNews.com Upgrades Adverum Biotechnologies (NASDAQ:ADVM) to Hold - Defense World
Adverum Biotechnologies' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Adverum Biotechnologies Inc Stock (ADVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):